Dec 2 (Reuters) - Immunocore Holdings PLC:
* IMMUNOCORE AND GADETA ANNOUNCE AGREEMENT TO DEVELOP FIRST GAMMA DELTA (ΓΔ) TCR IMMTAC FOR SOLID TUMORS
* IMMUNOCORE HOLDINGS PLC - CO HAS AN OPTION FOR EXCLUSIVE LICENSE TO FURTHER RESEARCH, DEVELOP AND COMMERCIALIZE IMMTAC CANDIDATES FROM COLLABORATION
* IMMUNOCORE HOLDINGS PLC - UNDER TERMS OF AGREEMENT, IMMUNOCORE AND GADETA WILL COLLABORATE ON '201 ΓΔ-TCR TARGET DISCOVERY
* IMMUNOCORE HOLDINGS- UNDER TERMS OF AGREEMENT, CO TO HAVE OPTION TO DEVELOP IMMTAC THERAPIES DERIVED FROM '201 TCR AS PART OF RESEARCH COLLABORATION Source text for Eikon: Further company coverage: